Liaoning OxiranchemInc（300082）株式概要遼寧オキシランケム有限公司は、中国においてハイエンドおよびエチレンオキシド誘導体のファインケミカルの研究開発、製造、販売を行っている。 詳細300082 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績1/6財務の健全性2/6配当金0/6報酬今年は黒字化を達成 リスク分析過去5年間で収益は年間52.5%減少しました。 財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見る300082 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW479,582 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA479,582 investors already sharing narrativesYour Fair ValueCN¥Current PriceCN¥7.05174.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-327m8b2016201920222025202620282031Revenue CN¥2.3bEarnings CN¥6.4mAdvancedSet Fair ValueView all narrativesLiaoning Oxiranchem,Inc. 競合他社Suzhou Kingswood Education TechnologySymbol: SZSE:300192Market cap: CN¥4.9bDongguan Changlian New Materials TechnologyLtdSymbol: SZSE:301618Market cap: CN¥4.1bJiangsu Canlon Building MaterialsSymbol: SZSE:300715Market cap: CN¥4.5bZhejiang Weihua New MaterialSymbol: SHSE:603310Market cap: CN¥4.9b価格と性能株価の高値、安値、推移の概要Liaoning OxiranchemInc過去の株価現在の株価CN¥7.0552週高値CN¥14.3852週安値CN¥6.38ベータ0.291ヶ月の変化-27.17%3ヶ月変化-45.56%1年変化-9.27%3年間の変化-10.31%5年間の変化n/aIPOからの変化-57.66%最新ニュースお知らせ • Jun 30Liaoning Oxiranchem,Inc. to Report First Half, 2026 Results on Aug 25, 2026Liaoning Oxiranchem,Inc. announced that they will report first half, 2026 results on Aug 25, 2026お知らせ • Apr 28Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026, at 15:30 China Standard Time. Location: The Company's Meeting Room, Shanghai Chinaお知らせ • Mar 31Liaoning Oxiranchem,Inc. to Report Q1, 2026 Results on Apr 28, 2026Liaoning Oxiranchem,Inc. announced that they will report Q1, 2026 results on Apr 28, 2026お知らせ • Dec 31Liaoning Oxiranchem,Inc. to Report Fiscal Year 2025 Results on Apr 28, 2026Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2025 results on Apr 28, 2026お知らせ • Sep 30Liaoning Oxiranchem,Inc. to Report Q3, 2025 Results on Oct 27, 2025Liaoning Oxiranchem,Inc. announced that they will report Q3, 2025 results on Oct 27, 2025お知らせ • Sep 12Liaoning Oxiranchem,Inc. Approves Board AppointmentsLiaoning Oxiranchem,Inc. at its EGM held on September 10, 2025, approved the appointment of Ren Jiangang and Liu Guocheng as independent directors.最新情報をもっと見るRecent updatesお知らせ • Jun 30Liaoning Oxiranchem,Inc. to Report First Half, 2026 Results on Aug 25, 2026Liaoning Oxiranchem,Inc. announced that they will report first half, 2026 results on Aug 25, 2026お知らせ • Apr 28Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026, at 15:30 China Standard Time. Location: The Company's Meeting Room, Shanghai Chinaお知らせ • Mar 31Liaoning Oxiranchem,Inc. to Report Q1, 2026 Results on Apr 28, 2026Liaoning Oxiranchem,Inc. announced that they will report Q1, 2026 results on Apr 28, 2026お知らせ • Dec 31Liaoning Oxiranchem,Inc. to Report Fiscal Year 2025 Results on Apr 28, 2026Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2025 results on Apr 28, 2026お知らせ • Sep 30Liaoning Oxiranchem,Inc. to Report Q3, 2025 Results on Oct 27, 2025Liaoning Oxiranchem,Inc. announced that they will report Q3, 2025 results on Oct 27, 2025お知らせ • Sep 12Liaoning Oxiranchem,Inc. Approves Board AppointmentsLiaoning Oxiranchem,Inc. at its EGM held on September 10, 2025, approved the appointment of Ren Jiangang and Liu Guocheng as independent directors.お知らせ • Jul 02Liaoning Oxiranchem,Inc. to Report First Half, 2025 Results on Aug 26, 2025Liaoning Oxiranchem,Inc. announced that they will report first half, 2025 results on Aug 26, 2025お知らせ • Apr 22Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2025Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: No. 38, Wanhe 7th Road, Hongwei District, Liaoyang, Liaoning Chinaお知らせ • Mar 31Liaoning Oxiranchem,Inc. to Report Q1, 2025 Results on Apr 22, 2025Liaoning Oxiranchem,Inc. announced that they will report Q1, 2025 results on Apr 22, 2025お知らせ • Dec 31Liaoning Oxiranchem,Inc. to Report Fiscal Year 2024 Results on Apr 22, 2025Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2024 results on Apr 22, 2025Reported Earnings • Oct 28Third quarter 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.061 loss in 3Q 2023)Third quarter 2024 results: CN¥0.05 loss per share (improved from CN¥0.061 loss in 3Q 2023). Revenue: CN¥1.17b (up 24% from 3Q 2023). Net loss: CN¥32.7m (loss narrowed 25% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.お知らせ • Sep 30Liaoning Oxiranchem,Inc. to Report Q3, 2024 Results on Oct 28, 2024Liaoning Oxiranchem,Inc. announced that they will report Q3, 2024 results on Oct 28, 2024New Risk • Sep 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).Reported Earnings • Aug 06Second quarter 2024 earnings released: CN¥0.032 loss per share (vs CN¥0.13 loss in 2Q 2023)Second quarter 2024 results: CN¥0.032 loss per share (improved from CN¥0.13 loss in 2Q 2023). Revenue: CN¥1.08b (down 2.1% from 2Q 2023). Net loss: CN¥22.4m (loss narrowed 75% from 2Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.お知らせ • Jun 29Liaoning Oxiranchem,Inc. to Report First Half, 2024 Results on Aug 06, 2024Liaoning Oxiranchem,Inc. announced that they will report first half, 2024 results on Aug 06, 2024Reported Earnings • Apr 24First quarter 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.09 loss in 1Q 2023)First quarter 2024 results: CN¥0.12 loss per share (further deteriorated from CN¥0.09 loss in 1Q 2023). Revenue: CN¥757.1m (down 19% from 1Q 2023). Net loss: CN¥78.4m (loss widened 30% from 1Q 2023).お知らせ • Apr 23Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2024Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: No. 38, Wanhe 7th Road, Hongwei District, Liaoyang, Liaoning ChinaNew Risk • Apr 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).お知らせ • Mar 30Liaoning Oxiranchem,Inc. to Report Q1, 2024 Results on Apr 23, 2024Liaoning Oxiranchem,Inc. announced that they will report Q1, 2024 results on Apr 23, 2024New Risk • Mar 21New major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.お知らせ • Dec 30Liaoning Oxiranchem,Inc. to Report Fiscal Year 2023 Results on Apr 23, 2024Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2023 results on Apr 23, 2024Reported Earnings • Oct 26Third quarter 2023 earnings released: CN¥0.061 loss per share (vs CN¥0.067 loss in 3Q 2022)Third quarter 2023 results: CN¥0.061 loss per share. Revenue: CN¥949.3m (down 35% from 3Q 2022). Net loss: CN¥43.6m (loss widened 12% from 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China.Reported Earnings • Aug 29Second quarter 2023 earnings released: CN¥0.13 loss per share (vs CN¥0.074 loss in 2Q 2022)Second quarter 2023 results: CN¥0.13 loss per share (further deteriorated from CN¥0.074 loss in 2Q 2022). Revenue: CN¥1.10b (down 30% from 2Q 2022). Net loss: CN¥89.8m (loss widened 73% from 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.Reported Earnings • Apr 19Full year 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.52 in FY 2021)Full year 2022 results: EPS: CN¥0.01 (down from CN¥0.52 in FY 2021). Revenue: CN¥5.64b (down 16% from FY 2021). Net income: CN¥5.60m (down 98% from FY 2021). Profit margin: 0.1% (down from 5.2% in FY 2021).Valuation Update With 7 Day Price Move • Mar 31Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥10.05, the stock trades at a trailing P/E ratio of 40.8x. Average trailing P/E is 28x in the Chemicals industry in China. Total loss to shareholders of 6.5% over the past year.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 29Third quarter 2022 earnings released: CN¥0.031 loss per share (vs CN¥0.16 profit in 3Q 2021)Third quarter 2022 results: CN¥0.031 loss per share (down from CN¥0.16 profit in 3Q 2021). Revenue: CN¥1.46b (down 22% from 3Q 2021). Net loss: CN¥39.0m (down 136% from profit in 3Q 2021). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.Board Change • Oct 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 20% share price gain to CN¥11.15, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 17x in the Chemicals industry in China.Reported Earnings • Aug 24Second quarter 2022 earnings released: CN¥0.074 loss per share (vs CN¥0.043 profit in 2Q 2021)Second quarter 2022 results: CN¥0.074 loss per share (down from CN¥0.043 profit in 2Q 2021). Revenue: CN¥1.58b (down 9.0% from 2Q 2021). Net loss: CN¥52.0m (down 261% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 22%, compared to a 42% growth forecast for the Chemicals industry in China.Reported Earnings • Apr 30First quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.08 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.08 in 1Q 2021). Revenue: CN¥1.34b (down 3.1% from 1Q 2021). Net income: CN¥99.7m (up 95% from 1Q 2021). Profit margin: 7.4% (up from 3.7% in 1Q 2021). The increase in margin was driven by lower expenses.Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Enjun Song was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 18Full year 2021 earnings released: EPS: CN¥0.53 (vs CN¥0.59 in FY 2020)Full year 2021 results: EPS: CN¥0.53 (down from CN¥0.59 in FY 2020). Revenue: CN¥6.72b (up 18% from FY 2020). Net income: CN¥357.2m (down 11% from FY 2020). Profit margin: 5.3% (down from 7.1% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 26%, compared to a 48% growth forecast for the industry in China.Board Change • Dec 10High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Enjun Song was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.株主還元300082CN ChemicalsCN 市場7D-3.4%-6.8%-4.7%1Y-9.3%24.2%10.6%株主還元を見る業界別リターン: 300082過去 1 年間で24.2 % の収益を上げたCN Chemicals業界を下回りました。リターン対市場: 300082は、過去 1 年間で10.6 % のリターンを上げたCN市場を下回りました。価格変動Is 300082's price volatile compared to industry and market?300082 volatility300082 Average Weekly Movement9.0%Chemicals Industry Average Movement7.7%Market Average Movement7.3%10% most volatile stocks in CN Market12.3%10% least volatile stocks in CN Market4.3%安定した株価: 300082 、 CN市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 300082の 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20001,362Zong Jiang Zhuwww.oxiranchem.com遼寧オキシランケム社は、中国でハイエンドおよびエチレンオキシド誘導体ファインケミカルの研究開発、製造、販売を行っている。同社は、医薬品、パーソナルケア、バイオベース界面活性剤、高機能材料、特殊添加剤など様々な用途に使用される結晶シリコン切削液、還元水剤、ポリエーテルモノマー、エチレンカーボネート製品、ポリエチレングリコールを提供している。同社の製品は、高速鉄道、地下鉄、空港、高速道路などのインフラ建設、洗浄剤、粉体洗浄剤、医薬品、電子材料、自動車、繊維、印刷インキ、染料などに使用されている。同社は2000年に設立され、中国遼陽市に本社を置いている。遼寧オキシランケム社はオキシランケムホールディンググループ社の子会社として運営されている。もっと見るLiaoning Oxiranchem,Inc. 基礎のまとめLiaoning OxiranchemInc の収益と売上を時価総額と比較するとどうか。300082 基礎統計学時価総額CN¥4.79b収益（TTM）CN¥12.15m売上高(TTM)CN¥4.35b394.8xPER（株価収益率1.1xP/Sレシオ300082 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計300082 損益計算書（TTM）収益CN¥4.35b売上原価CN¥4.16b売上総利益CN¥194.83mその他の費用CN¥182.69m収益CN¥12.15m直近の収益報告Mar 31, 2026次回決算日Aug 25, 2026一株当たり利益（EPS）0.018グロス・マージン4.47%純利益率0.28%有利子負債／自己資本比率68.8%300082 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 22:23終値2026/07/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Liaoning Oxiranchem,Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Di WuChina International Capital Corporation LimitedNai Di ZhaoEverbright Securities Co. Ltd.Fangbiao ZhengIndustrial Securities Co. Ltd.
お知らせ • Jun 30Liaoning Oxiranchem,Inc. to Report First Half, 2026 Results on Aug 25, 2026Liaoning Oxiranchem,Inc. announced that they will report first half, 2026 results on Aug 25, 2026
お知らせ • Apr 28Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026, at 15:30 China Standard Time. Location: The Company's Meeting Room, Shanghai China
お知らせ • Mar 31Liaoning Oxiranchem,Inc. to Report Q1, 2026 Results on Apr 28, 2026Liaoning Oxiranchem,Inc. announced that they will report Q1, 2026 results on Apr 28, 2026
お知らせ • Dec 31Liaoning Oxiranchem,Inc. to Report Fiscal Year 2025 Results on Apr 28, 2026Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2025 results on Apr 28, 2026
お知らせ • Sep 30Liaoning Oxiranchem,Inc. to Report Q3, 2025 Results on Oct 27, 2025Liaoning Oxiranchem,Inc. announced that they will report Q3, 2025 results on Oct 27, 2025
お知らせ • Sep 12Liaoning Oxiranchem,Inc. Approves Board AppointmentsLiaoning Oxiranchem,Inc. at its EGM held on September 10, 2025, approved the appointment of Ren Jiangang and Liu Guocheng as independent directors.
お知らせ • Jun 30Liaoning Oxiranchem,Inc. to Report First Half, 2026 Results on Aug 25, 2026Liaoning Oxiranchem,Inc. announced that they will report first half, 2026 results on Aug 25, 2026
お知らせ • Apr 28Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026, at 15:30 China Standard Time. Location: The Company's Meeting Room, Shanghai China
お知らせ • Mar 31Liaoning Oxiranchem,Inc. to Report Q1, 2026 Results on Apr 28, 2026Liaoning Oxiranchem,Inc. announced that they will report Q1, 2026 results on Apr 28, 2026
お知らせ • Dec 31Liaoning Oxiranchem,Inc. to Report Fiscal Year 2025 Results on Apr 28, 2026Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2025 results on Apr 28, 2026
お知らせ • Sep 30Liaoning Oxiranchem,Inc. to Report Q3, 2025 Results on Oct 27, 2025Liaoning Oxiranchem,Inc. announced that they will report Q3, 2025 results on Oct 27, 2025
お知らせ • Sep 12Liaoning Oxiranchem,Inc. Approves Board AppointmentsLiaoning Oxiranchem,Inc. at its EGM held on September 10, 2025, approved the appointment of Ren Jiangang and Liu Guocheng as independent directors.
お知らせ • Jul 02Liaoning Oxiranchem,Inc. to Report First Half, 2025 Results on Aug 26, 2025Liaoning Oxiranchem,Inc. announced that they will report first half, 2025 results on Aug 26, 2025
お知らせ • Apr 22Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2025Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: No. 38, Wanhe 7th Road, Hongwei District, Liaoyang, Liaoning China
お知らせ • Mar 31Liaoning Oxiranchem,Inc. to Report Q1, 2025 Results on Apr 22, 2025Liaoning Oxiranchem,Inc. announced that they will report Q1, 2025 results on Apr 22, 2025
お知らせ • Dec 31Liaoning Oxiranchem,Inc. to Report Fiscal Year 2024 Results on Apr 22, 2025Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2024 results on Apr 22, 2025
Reported Earnings • Oct 28Third quarter 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.061 loss in 3Q 2023)Third quarter 2024 results: CN¥0.05 loss per share (improved from CN¥0.061 loss in 3Q 2023). Revenue: CN¥1.17b (up 24% from 3Q 2023). Net loss: CN¥32.7m (loss narrowed 25% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
お知らせ • Sep 30Liaoning Oxiranchem,Inc. to Report Q3, 2024 Results on Oct 28, 2024Liaoning Oxiranchem,Inc. announced that they will report Q3, 2024 results on Oct 28, 2024
New Risk • Sep 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).
Reported Earnings • Aug 06Second quarter 2024 earnings released: CN¥0.032 loss per share (vs CN¥0.13 loss in 2Q 2023)Second quarter 2024 results: CN¥0.032 loss per share (improved from CN¥0.13 loss in 2Q 2023). Revenue: CN¥1.08b (down 2.1% from 2Q 2023). Net loss: CN¥22.4m (loss narrowed 75% from 2Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
お知らせ • Jun 29Liaoning Oxiranchem,Inc. to Report First Half, 2024 Results on Aug 06, 2024Liaoning Oxiranchem,Inc. announced that they will report first half, 2024 results on Aug 06, 2024
Reported Earnings • Apr 24First quarter 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.09 loss in 1Q 2023)First quarter 2024 results: CN¥0.12 loss per share (further deteriorated from CN¥0.09 loss in 1Q 2023). Revenue: CN¥757.1m (down 19% from 1Q 2023). Net loss: CN¥78.4m (loss widened 30% from 1Q 2023).
お知らせ • Apr 23Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2024Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: No. 38, Wanhe 7th Road, Hongwei District, Liaoyang, Liaoning China
New Risk • Apr 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
お知らせ • Mar 30Liaoning Oxiranchem,Inc. to Report Q1, 2024 Results on Apr 23, 2024Liaoning Oxiranchem,Inc. announced that they will report Q1, 2024 results on Apr 23, 2024
New Risk • Mar 21New major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
お知らせ • Dec 30Liaoning Oxiranchem,Inc. to Report Fiscal Year 2023 Results on Apr 23, 2024Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2023 results on Apr 23, 2024
Reported Earnings • Oct 26Third quarter 2023 earnings released: CN¥0.061 loss per share (vs CN¥0.067 loss in 3Q 2022)Third quarter 2023 results: CN¥0.061 loss per share. Revenue: CN¥949.3m (down 35% from 3Q 2022). Net loss: CN¥43.6m (loss widened 12% from 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China.
Reported Earnings • Aug 29Second quarter 2023 earnings released: CN¥0.13 loss per share (vs CN¥0.074 loss in 2Q 2022)Second quarter 2023 results: CN¥0.13 loss per share (further deteriorated from CN¥0.074 loss in 2Q 2022). Revenue: CN¥1.10b (down 30% from 2Q 2022). Net loss: CN¥89.8m (loss widened 73% from 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
Reported Earnings • Apr 19Full year 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.52 in FY 2021)Full year 2022 results: EPS: CN¥0.01 (down from CN¥0.52 in FY 2021). Revenue: CN¥5.64b (down 16% from FY 2021). Net income: CN¥5.60m (down 98% from FY 2021). Profit margin: 0.1% (down from 5.2% in FY 2021).
Valuation Update With 7 Day Price Move • Mar 31Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥10.05, the stock trades at a trailing P/E ratio of 40.8x. Average trailing P/E is 28x in the Chemicals industry in China. Total loss to shareholders of 6.5% over the past year.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 29Third quarter 2022 earnings released: CN¥0.031 loss per share (vs CN¥0.16 profit in 3Q 2021)Third quarter 2022 results: CN¥0.031 loss per share (down from CN¥0.16 profit in 3Q 2021). Revenue: CN¥1.46b (down 22% from 3Q 2021). Net loss: CN¥39.0m (down 136% from profit in 3Q 2021). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.
Board Change • Oct 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 20% share price gain to CN¥11.15, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 17x in the Chemicals industry in China.
Reported Earnings • Aug 24Second quarter 2022 earnings released: CN¥0.074 loss per share (vs CN¥0.043 profit in 2Q 2021)Second quarter 2022 results: CN¥0.074 loss per share (down from CN¥0.043 profit in 2Q 2021). Revenue: CN¥1.58b (down 9.0% from 2Q 2021). Net loss: CN¥52.0m (down 261% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 22%, compared to a 42% growth forecast for the Chemicals industry in China.
Reported Earnings • Apr 30First quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.08 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.08 in 1Q 2021). Revenue: CN¥1.34b (down 3.1% from 1Q 2021). Net income: CN¥99.7m (up 95% from 1Q 2021). Profit margin: 7.4% (up from 3.7% in 1Q 2021). The increase in margin was driven by lower expenses.
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Enjun Song was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 18Full year 2021 earnings released: EPS: CN¥0.53 (vs CN¥0.59 in FY 2020)Full year 2021 results: EPS: CN¥0.53 (down from CN¥0.59 in FY 2020). Revenue: CN¥6.72b (up 18% from FY 2020). Net income: CN¥357.2m (down 11% from FY 2020). Profit margin: 5.3% (down from 7.1% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 26%, compared to a 48% growth forecast for the industry in China.
Board Change • Dec 10High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Enjun Song was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
